{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:29:11Z","timestamp":1791894551357,"version":"4.3.4"},"reference-count":99,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chimeric antigen receptor T-cell (or CAR-T) therapy and bispecific antibodies (BsAbs) have revolutionized the treatment of hematologic malignancies, offering new options for relapsed or refractory cases. However, these therapies carry risks of early complications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and delayed issues like graft-versus-host disease (GVHD), infections, and secondary cancers. Effective management requires early diagnosis using advanced biomarkers and imaging, along with prompt interventions involving immunosuppressants, corticosteroids, and cytokine inhibitors. A multidisciplinary approach is essential, integrating hematologists, oncologists, and infectious disease specialists, with emerging strategies like targeted biologics and personalized medicine showing promise in balancing efficacy with toxicity management. Ongoing research is critical to refine diagnostics and treatments, ensuring that these therapies not only extend survival but also improve patients\u2019 quality of life. This review provides critical insights for healthcare professionals to quickly recognize and treat complications of CAR-T and BsAbs therapies. By focusing on early detection through biomarkers and imaging and outlining timely therapeutic interventions, it aims to equip the multidisciplinary care team with the knowledge necessary to manage the challenges of these advanced treatments effectively, ultimately optimizing patient outcomes.<\/jats:p>","DOI":"10.3390\/cancers17020282","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:33:02Z","timestamp":1737084782000},"page":"282","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-2480","authenticated-orcid":false,"given":"Ayrton","family":"Bangolo","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Amoozgar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Mansour","sequence":"additional","affiliation":[{"name":"Rutgers New Jersey Medical School, Newark, NJ 07103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-4970","authenticated-orcid":false,"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvarinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5618","authenticated-orcid":false,"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplant and Cellular Therapy, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_5","first-page":"188","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yang, C., Nguyen, J., and Yen, Y. (2023). Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00982-8"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/hematology.2023000438","article-title":"Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas","volume":"2023","author":"Major","year":"2023","journal-title":"Hematology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zeiser, R., Ringden, O., Sadeghi, B., Gonen-Yaacovi, G., and Segurado, O.G. (2023). Novel therapies for graft versus host disease with a focus on cell therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1241068"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1182\/blood-2024-193052","article-title":"Future Landscapes of Bispecific Antibodies in Chronic Lymphocytic Leukemia (CLL). Systematic Review of Ongoing Trials","volume":"144","author":"Shahzad","year":"2024","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific antibodies in hematological malignancies: A scoping review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11912-019-0759-5","article-title":"Bispecific antibodies in hematologic malignancies: When, to whom, and how should be best used?","volume":"21","author":"Bourlon","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor t cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: A systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3324\/haematol.2023.284604","article-title":"Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Locatelli","year":"2024","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced ALL","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia: A multicenter, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","article-title":"Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy","volume":"14","author":"Merz","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2024-200050","article-title":"CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia","volume":"144","author":"Benjamini","year":"2024","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for Richter\u2019s transformation: An international multicenter retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"ref_27","unstructured":"Roche (2025, January 01). A Study to Evaluate Glofitamab as a Single Agent vs. Investigator\u2019s Choice in Participants with Relapsed\/Refractory Mantle Cell Lymphoma (GO46084). ClinicalTrials.gov. Published September 2023, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06084936."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bento, L., Glass, B., and Schmitz, N. (2024). Large B-Cell Lymphoma. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-031-44080-9_86"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wu, X., Sun, X., Deng, W., Xu, R., and Zhao, Q. (2024). Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma. Heliyon, 10.","DOI":"10.1016\/j.heliyon.2024.e34068"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1182\/blood-2024-202561","article-title":"Efficacy and Safety of Mosunetuzumab in Relapsed\/Refractory Non-Hodgkin Lymphoma: A Systematic Review","volume":"144","author":"Elemian","year":"2024","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","article-title":"Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids","volume":"59","author":"Oluwole","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_33","first-page":"1652","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","article-title":"Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor\u2013engineered T cells","volume":"343","author":"Xu","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_35","first-page":"2149","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Radtke, K.K., Bender, B.C., Li, Z., Turner, D.C., Roy, S., Belousov, A., and Li, C.-C. (2024). Clinical Pharmacology of Cytokine Release Syndrome with T-Cell\u2013Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. Clin. Cancer Res., OF1\u2013OF13.","DOI":"10.1158\/1078-0432.CCR-24-2247"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., and Olszewska, M. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6.","DOI":"10.1126\/scitranslmed.3008226"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Velasco, R., Mussetti, A., Villagr\u00e1n-Garc\u00eda, M., and Sureda, A. (2023). CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1144414"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"ref_42","first-page":"121","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: A LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bindal, P., Trottier, C.A., Elavalakanar, P., Dodge, L.E., Kim, S., Logan, E., Ma, S., Liegel, J., Arnason, J., and Alonso, C.D. (2024). Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy. Leuk. Lymphoma, 1\u201311.","DOI":"10.1080\/10428194.2024.2439513"},{"key":"ref_45","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Penack, O., Peczynski, C., Koenecke, C., Polge, E., Kuhnl, A., Fegueux, N., Daskalakis, M., Kr\u00f6ger, N., Dreger, P., and Besley, C. (2023). Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party. J. Immunother. Cancer, 11.","DOI":"10.1136\/jitc-2022-006406"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","first-page":"925","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ofad500.2305","DOI":"10.1093\/ofid\/ofad500.2305","article-title":"2694. Infectious Complications in CAR-T Cell Therapy Recipients: A Systematic Review and Meta-Analysis","volume":"Volume 10","author":"Banegas","year":"2023","journal-title":"Open Forum Infectious Diseases"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41409-022-01771-x","article-title":"Management of prolonged cytopenia following CAR T-cell therapy","volume":"57","author":"Corona","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","article-title":"New insights into CAR T-cell hematological toxicities: Manifestations, mechanisms, and effective management strategies","volume":"13","author":"Yang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bouziana, S., and Bouzianas, D. (2024). The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179518"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, P., Liu, M., Lyu, C., Lu, W., Cui, R., Wang, J., Li, Q., Mou, N., Deng, Q., and Yang, D. (2020). Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.573822"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/asheducation-2018.1.228","article-title":"Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation","volume":"2018","author":"Hamilton","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Olivieri, A., and Mancini, G. (2024). Current approaches for the prevention and treatment of acute and chronic GVHD. Cells, 13.","DOI":"10.3390\/cells13181524"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2023011669","article-title":"Impact of diagnostic investigations in the management of CAR T-cell\u2013associated neurotoxicity","volume":"8","author":"Mauget","year":"2024","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-020-00935-6","article-title":"Neurological complications of CAR T cell therapy","volume":"22","author":"Landry","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.6004\/jnccn.2023.5033","article-title":"Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies","volume":"21","author":"Oluwole","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wudhikarn, K., Soh, S.Y., Huang, H., and Perales, M.A. (2021). Toxicity of Chimeric Antigen Receptor T Cells and its Management. Blood Cell Therapy, 4.","DOI":"10.31547\/bct-2021-011"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/1060028020988411","article-title":"A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: Engaging an old problem with new solutions","volume":"55","author":"Halford","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"van de Donk, N.W., Moreau, P., Garfall, A.L., Bhutani, M., Oriol, A., Nooka, A.K., Martin, T.G., Rosi\u00f1ol, L., Mateos, M.V., and Bahlis, N.J. (2023). Long-term follow-up fromMajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol., 7.","DOI":"10.1016\/S2152-2650(23)00857-1"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2024-211076","article-title":"Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study","volume":"144","author":"Yang","year":"2024","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma (118\/120 characters)","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Shah, D., Soper, B., and Shopland, L. (2023). Cytokine release syndrome and cancer immunotherapies\u2013historical challenges and promising futures. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1190379"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7 CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., and Cavo, M. (2024). Bispecific antibodies for the management of relapsed\/refractory multiple myeloma. Cancers, 16.","DOI":"10.3390\/cancers16132337"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Usmani","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Lancman, G., Song, K., White, D., Crosbie, T., Sharif, I., Emond, M., Raza, M.S., Elias, M., Kaedbey, R., and Chu, M.P. (2024). Recommendations for the effective use of T-cell\u2013redirecting therapies: A Canadian consensus statement. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1446995"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10238-024-01520-y","article-title":"Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape","volume":"25","author":"Verma","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"Fassi","year":"2023","journal-title":"Hematology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bayly-McCredie, E., Treisman, M., and Fiorenza, S. (2024). Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179736"},{"key":"ref_84","first-page":"S209","article-title":"Incidence, Characteristics, and Management of Adverse Events with Bispecific T Cell Engagers for Relapsed or Refractory Multiple Myeloma: A Systematic Review","volume":"30","author":"Faiz","year":"2024","journal-title":"Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Topp, M., and Feuchtinger, T. (2022). Management of hypogammaglobulinaemia and B-cell aplasia. The EBMT\/EHA CAR-T Cell Handbook, Springer.","DOI":"10.1007\/978-3-030-94353-0_28"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","article-title":"Bispecific antibodies for autoimmune and inflammatory diseases: Clinical progress to date","volume":"34","author":"Zhao","year":"2020","journal-title":"BioDrugs"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., and Qian, C. (2021). Bispecific antibodies: From research to clinical application. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.626616"},{"key":"ref_90","first-page":"357","article-title":"Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen","volume":"109","author":"Piron","year":"2023","journal-title":"Haematologica"},{"key":"ref_91","unstructured":"Dietrich, J., and Frigault, M.J. (2021). Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), UpToDate."},{"key":"ref_92","first-page":"3681","article-title":"T-cell\u2013redirecting bispecific antibodies in multiple myeloma: A revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102189","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Tix","year":"2024","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: Opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Ellerman, D.A. (2024). The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds. BioDrugs, 1\u201328.","DOI":"10.1007\/s40259-024-00691-0"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Li, C.L., Ma, X.Y., and Yi, P. (2024). Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody\u2212 Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects. Cell Biochem. Funct., 42.","DOI":"10.1002\/cbf.70011"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/282\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:16Z","timestamp":1759919416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":99,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020282"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020282","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}